全球地诺单抗市场 – 行业趋势及 2030 年预测

地诺单抗市场分析和规模

骨质疏松症的发病率往往会随着年龄的增长而增加，尤其是绝经后女性，这是由于绝经期间激素水平发生变化所致。然而，骨质疏松症也会影响男性和年轻人。根据国际骨质疏松基金会 (IOF) 的数据，全球约有 2 亿女性患有骨质疏松症。此外，50 岁以上的女性中约有三分之一和 5 岁以上的男性中约有五分之一会在一生中经历骨质疏松性骨折。

Data Bridge Market Research 分析，全球地诺单抗市场规模在 2022 年为 28.9217 亿美元，到 2030 年将飙升至 71.0992 亿美元，预计在预测期内的复合年增长率为 11.9%。这表明了市场价值。由于对骨相关疾病更好治疗的需求不断增长，“Prolia”在全球地诺单抗市场的药物分类部分占据主导地位。

除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Denosumab injection (Prolia) refers to the type of drug that is utilized for treating osteoporosis, which is a condition in which the bones become thin and weak and breaks easily among the women population. The condition occurs mainly in women who have undergone menopause and have an increased risk for fractures.

Global Denosumab Market Dynamics

Drivers

• Increasing Prevalence of Osteoporosis

Osteoporosis is a common condition characterized by decreased bone density and increased risk of fractures. As the global population ages, the prevalence of osteoporosis is expected to rise, driving the demand for medications like Denosumab that can help prevent fractures and improve bone health.

• Growing Awareness and Diagnosis

With increased awareness about osteoporosis and its impact on overall health, more individuals are seeking diagnosis and treatment. This increased awareness and diagnosis contribute to the demand for medications like Denosumab.

• Efficacy and Safety Profile for Expanded Indications

Denosumab has demonstrated efficacy in reducing the risk of fractures and improving bone density in clinical trials. Its safety profile, when used as directed, has been generally well-tolerated. These factors contribute to its popularity and adoption in the market. Denosumab has received approvals for additional indications beyond osteoporosis, such as the prevention of skeletal-related events in patients with bone metastases from solid tumors and the treatment of giant cell tumors of bone. These expanded indications have widened the market for Denosumab.

Opportunities

• Research and Development Proficiencies

Ongoing research and development efforts in the field of bone health provide opportunities for the development of new therapies and combination treatments. Denosumab manufacturers can explore these opportunities to further optimize the efficacy and safety of Denosumab or develop novel treatments that complement its mechanism of action.

• Increasing Aging Population

The global population is aging, with a larger proportion of elderly individuals. As age is a significant risk factor for osteoporosis and other bone-related conditions, this demographic trend presents a substantial opportunity for the Denosumab market to cater to the growing demand for bone health treatments.

Restraints/Challenges

• Competition from Existing Therapies

Denosumab faces competition from other established therapies for osteoporosis treatment, such as bisphosphonates and selective estrogen receptor modulators. These therapies have been widely used and have a long history of efficacy and safety, making it challenging for Denosumab to gain market share.

• High Cost of Denosumab Therapy and Treatment

Denosumab is a biologic therapy, and biologics often come with a higher cost compared to traditional small molecule drugs. The high cost of Denosumab may limit its accessibility and affordability for some patients, especially in regions with limited healthcare resources or inadequate insurance coverage.

• Long-term Safety and Efficacy Data

While Denosumab has demonstrated efficacy and safety in clinical trials, long-term data on its use beyond several years is limited. The availability of long-term safety and efficacy data is crucial to gain the confidence of healthcare providers and patients, especially for chronic conditions like osteoporosis.

• Complex Reimbursement Challenges

Reimbursement policies and pricing negotiations with healthcare systems and insurance providers can pose challenges for Denosumab manufacturers. The availability of reimbursement and formulary coverage may vary across different regions, impacting patient access and market penetration.

This global denosumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Denosumab market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In February 2023, Sandoz announced that the biologics license application (BLA) for its denosumab biosimilar candidate for review had been accepted by the Food and Drug Administration (FDA) for the treatment of premenopausal patients with osteoporosis who are at increased risk of fractures
• In November 2022, Luye Pharma Group’s subsidiary Boan Biotech announced that their Denosumab Injection (Boyoubei) got approval for the product launch in China by the National Medical Products Administration (NMPA) for the treatment of postmenopausal women with osteoporosis at high risk of fractures.

Global Denosumab Market Scope

The global denosumab market is segmented on the basis of drug classification, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Classification

• Prolia
• Xgeva
• Others

 End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Denosumab Market Regional Analysis/Insights

The global denosumab market is analysed, and market size insights and trends are provided by country, drug classification, end-users, and distribution channel as referenced above.

The countries covered in the global denosumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

North America is expected to dominate the global denosumab market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having bone disorders, mostly women.

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for diagnosis and treatment, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

全球地舒单抗市场还为您提供详细的市场分析，包括每个国家/地区资本设备医疗保健支出的增长、全球地舒单抗市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对全球地舒单抗市场的影响。预测期为 2015-2020 年。

竞争格局和全球地诺单抗市场份额分析

全球地舒单抗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球地舒单抗市场的关注有关。

全球地诺单抗市场的一些主要参与者包括：

• 默克公司（美国）
• Amneal Pharmaceutical Inc（美国）
• 梯瓦制药工业有限公司 (以色列)
• Zydus Cadila（印度）
• 诺华公司（瑞士）
• 辉瑞公司 (美国)
• 阿斯利康（英国）
• 葛兰素史克公司 (英国)
• 百时美施贵宝公司 (美国)
• 强生服务公司（美国）
• F. Hoffmann-La Roche Ltd（瑞士）
• 拜耳公司（德国）
• 安进公司 (美国)
• 赛诺菲（法国）
• Biogen（美国）
• 再生元制药公司 (美国)
• 礼来公司（美国）
• AbbiVie Inc（美国）
• Mylan NV（美国）
• 卫材株式会社（日本）

SKU-67522